Status: Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
Participants needed: 180
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Olema Pharmaceuticals, Inc.Updated: Oct 10, 2025Locations: 8
Eligibility criteria
Participants with advanced or metastatic ER+HER2- breast cancer, mCRPC, or NSCLC... [+6]
Prior therapy with KAT6A/B inhibitor in any treatment setting. [+4]